Exelixis Stock Today
| EXEL Stock | USD 35.00 0.51 1.48% |
PerformanceWeak
| Odds Of DistressVery Low
|
Exelixis is selling for 35.00 as of the 17th of February 2025. This is a 1.48 percent increase since the beginning of the trading day. The stock's lowest day price was 34.18. Exelixis has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 18th of January 2025 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of April 2000 | Category Healthcare | Classification Health Care |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. The company has 279.88 M outstanding shares of which 13.09 M shares are currently shorted by private and institutional investors with about 4.89 trading days to cover. More on Exelixis
Moving against Exelixis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Exelixis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Michael Morrissey | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, SP Midcap 400, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsExelixis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Exelixis' financial leverage. It provides some insight into what part of Exelixis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exelixis (EXEL) is traded on NASDAQ Exchange in USA. It is located in 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 and employs 1,310 people. Exelixis is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.8 B. Exelixis conducts business under Biotechnology sector and is part of Health Care industry. The entity has 279.88 M outstanding shares of which 13.09 M shares are currently shorted by private and institutional investors with about 4.89 trading days to cover.
Exelixis currently holds about 1.53 B in cash with 699.97 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77.
Check Exelixis Probability Of Bankruptcy
Ownership AllocationExelixis holds a total of 279.88 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Exelixis Ownership Details
Exelixis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 3.3 M | |
| Aqr Capital Management Llc | 2024-09-30 | 3.2 M | |
| Stephens Inv Mgmt Group Llc | 2024-12-31 | 3.1 M | |
| First Trust Advisors L.p. | 2024-09-30 | 2.9 M | |
| Norges Bank | 2024-12-31 | 2.8 M | |
| Fmr Inc | 2024-09-30 | 2.5 M | |
| Bank Of New York Mellon Corp | 2024-12-31 | 2.5 M | |
| Los Angeles Capital Management Llc | 2024-12-31 | 2.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 M | |
| Blackrock Inc | 2024-09-30 | 32.1 M | |
| Vanguard Group Inc | 2024-12-31 | 29.4 M |
Exelixis Historical Income Statement
Exelixis Stock Against Markets
Exelixis Corporate Management
| Amy MD | Product VP | Profile | |
| Laura Dillard | Executive Resources | Profile | |
| Tony Redmond | Senior Resources | Profile | |
| Gregg Bernier | VP Marketing | Profile | |
| William MD | Senior Affairs | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.754 | Earnings Share 1.76 | Revenue Per Share | Quarterly Revenue Growth 0.182 | Return On Assets |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.